ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint modulators with a highly-differentiated & diversified portfolio of first-in-class therapeutic antibodies in cancers and auto-immunity. With a "precision medicine-based" translational approach and several established academic collaborations with renowned institutions, ImCheck is uniquely positioned to develop theragnostic candidates for precision & personalized medicine in cancers and auto-immunity diseases. To-date, ImCheck is developing two first-in-class immunomodulator antibodies and is advancing several discovery programs on undisclosed targets, all playing a defined immune-modulating role in both innate and adaptive immunity. Member of the European immunology cluster Marseille Immunopole (MI), ImCheck is based within the Institut Paoli-Calmettes in Marseille and is engaged in an active recruitment effort.
|Core business:||Life sciences technologies company (therapeutics, diagnosis...)|
|Business axis:||diagnostic - medicament|
|Number of employees:||33|
180 avenue du Prado 13008
Back to the members directory